Scarica l'app Stockscreener
13.49
3.30%
-0.46
Dopo l'orario di chiusura:
13.50
0.010
+0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLS Giù?
Forum
Previsione
Frazionamento azionario
Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
SLS Stock Hits Over 5-Year High: Retail Traders Bet Big On Breaking $25 As AML Readout Looms - Stocktwits
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation - Stocktwits
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum - Stocktwits
Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today? - Stocktwits
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Stocktwits
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - GlobeNewswire Inc.
SLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout Chatter - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Encourages SELLAS Life Sciences Group, Inc. (SLS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages SELLAS Life Science - The National Law Review
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential - Stocktwits
SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy - Stocktwits
SLS Stock Rises Overnight: Why Retail Traders Prefer Sellas Over IBRX, ONDS, PYPL As Most Bullish Pick - Stocktwits
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger - Stocktwits
SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEO’s Fox Appearance - Stocktwits
SELLAS Life Sciences Group, Inc. (SLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
SLS Stock Pops After-Hours As Loss Shrinks, Cash Swells — All Eyes On High Stakes AML Trial In 'Pivotal' 2026 - Stocktwits
SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas - Stocktwits
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology - Stocktwits
SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger - Stocktwits
SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute - Stocktwits
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits
SLS Stock Logs Record H1 As AML Trial Nears Finish Line — Why Are Retail Traders Refusing To Cash Out? - Stocktwits
SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst - Stocktwits
SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against SELLAS Life Sciences Group, Inc. (SLS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers - Stocktwits
SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Sellas Gears Up To Present Preclinical SLS009 Data For Pancreatic Cancer At Major Oncology Conference - Yahoo Finance
SELLAS Life Sciences to Present Preclinical Data on SLS009 - GlobeNewswire
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer - Yahoo Finance
Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here - Barchart.com
SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED) - Yahoo Finance
Sellas CEO Stergiou Says ‘Rigorous, Unblinded’ Data From Pivotal AML Trial Will 'Speak For Itself' As REGAL Catalyst Nears - finance.yahoo.com
BMF Capital Shorts SELLAS Life Sciences, Sees 76% DownsideSELLAS Life Sciences Gr (NASDAQ:SLS) - Benzinga
Is Uncertain Galinpepimut-S Data Timing Reshaping SELLAS Life Sciences Group’s (SLS) Strategic Story? - webull.com
When Will SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Breakeven? - 富途牛牛
SELLAS Life Sciences Group Stock (SLS) Opinions on REGAL Trial Catalyst - Quiver Quantitative
SELLAS Life Sciences Group, Inc. Tokenized Stock (Robinhood) - CryptoRank
SELLAS Life Sciences Group, Inc. Tokenized Stock (Robinhood) Exchanges SLS Markets | Buy & Sell & Trade - CryptoRank
SELLAS Life Sciences Jumps 300% YTD as FDA Approval of Rival Pancreatic Cancer Pill Fuels Speculation - finance.biggo.com
Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline - Stocktwits
SLS Traders Eye This Important Resistance Zone Ahead Of Key AML Data Readout - Stocktwits
SLS Stock Charges Ahead As AML Trial Buzz Builds: Report Claims Regal Hit 80th Event — Retail Isn’t Convinced - Stocktwits
SELLAS Shares Gain $416 Million With REGAL Trial Approaching Final Analysis - TechStock²
Are SELLAS Life Sciences (SLS) Loss Trends Masking a Shifting Cancer Vaccine Investment Narrative? - simplywall.st
Sellas Life Sciences Rides a Sector Wave as Its Own Leukemia Trial Hits the Home Stretch - Ad-hoc-news.de
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):